Human Insulin Market Strategies, Competitive Landscape and Forecast to 2025
Market Overview:
Human Insulin Market Shareis expected to grow atCAGR of 12.10%to reach USD 90,812.40 Million till 2025. Human insulin in the report refers to synthetic insulin manufactured in laboratories by increasing insulin protein with the help of e. coli bacteria. Human insulin can be administered orally or through insulin infusion devices. Some conventional insulin infusion devices are syringes, injection pens, and insulin pumps. These devices are used to deliver insulin on time and regularly.
Get a Free Sample @ https://www.marketresearchfuture.com/sample_request/951
Human insulin is a form of synthetic insulin that is grown to mimic human insulin. Before the development of human insulin, which was first approved for pharmaceutical use in 1982, pig insulin was the most common solution in use. Human insulin is generated by growing insulin proteins within the E. coli bacteria.The growing development of the medical research sector has proven highly beneficial for the global human insulin market, as increasing efforts have been made for the development of highly sophisticated human insulin products.
The growing prevalence of diabetes is likely to be the major driver for the global human insulin market over the forecast period. The threat of diabetes has grown in developed countries as a result of the increasing consumption of sugar-rich, unhealthy foods, allied to a mostly sedentary lifestyle. The increasing Westernization of the dietary patterns in developing countries has also led to a significant growth in the prevalence of diabetes in emerging regions such as Asia Pacific, which is likely to drive the human insulin market over the forecast period.
Segmentation:
· Based on type, the global Human Insulin Market has been segmented into traditional human insulin and modern human insulin. Traditional human insulin segment includes premixed traditional, intermediate-acting, and short-acting. Modern human insulin segment includes premixed modern, long-acting, and rapid-acting. Modern human insulin was the leading segment in 2018. Modern human insulin, also known as analog insulin, is prescribed by physicians for the treatment of diabetes. It is the customized form of traditional human insulin and provides effective results in comparison to traditional human insulin.
· The global human insulin market, by brand, has been segmented into Lantus, Novorapid, Humalog, Novomix, Levemir, Apidar, Humulin, and Insuman. Lantus is a long-acting human insulin analog, and it is available in more than 120 countries. Among all the brands, Lantus commands the largest share in the human insulin market. Apidra is a rapid acting human insulin analog. Also, Apidra and Levemir are the fastest growing brand in the human insulin market. Moreover, there are various drugs in the pipeline, which would have a positive impact on the growth of the market in the coming years.
Regional Analysis:
Regionally, the global human insulin market is segmented into North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America is expected to remain the leading contributor to the global human insulin market over the forecast period due to the growing prevalence of diabetes in the region and the presence of advanced research avenues responsible for creating the most modern and sophisticated versions of human insulin. The growing obesity problem in North America has also played its part in the growth in the prevalence of diabetes in the region and is likely to remain a major driver for the human insulin market in the region over the forecast period.
Europe is also likely to remain a major regional market for human insulin over the forecast period and is expected to take up the second position in the global human insulin market charts. Developed Western European countries such as Germany, France, and the UK are the leading regional markets for human insulin, as these countries have witnessed the highest prevalence of diabetes in Europe and are likely to remain major consumers of human insulin products over the forecast period.
Access Full Report Details @ https://www.marketresearchfuture.com/reports/human-insulin-market-951
The Asia Pacific market for human insulin is expected to grow spectacularly over the forecast period due to the growing prevalence of diabetes and increasing awareness about the availability and benefits of human insulin. The increasing popularity of Western food products in Asia Pacific countries such as China, Japan, Korea, and India has led to a rising prevalence of obesity and consequently diabetes, which is likely to drive the human insulin market in the region over the forecast period. As of January 2019, anti-diabetes medications had witnessed a 12.9% y-o-y growthin India and accounted for close to a fifth of the overall pharmaceutical market in the country, illustrating the rising need to check the spread ofdiabetes.